Healios K.K.

4593

JP3835100003

Biotechnology & Medical Research

Delayed Japan Exchange Other stock markets 11:30:00 02/07/2024 am IST			5-day change	1st Jan Change
174 ^JPY	-5.95%		-5.95%	+5.45%

20/06	Healios to Book $3 Million Upfront Payment as Sales Revenue in Q2 Following License Deal with Astellas Institute	MT
19/06	Healios K.K. Enters into License Agreement with Astellas Institute for Regenerative Medicine	CI

Healios K.K. Announces Retirement of Ken Ishikawa, Director

February 26, 2019 at 11:30 am IST

Healios K.K. announced the retirement of Ken Ishikawa, Director from the board at the expiration of term on March 27, 2019.

Latest news about Healios K.K.

Healios to Book $3 Million Upfront Payment as Sales Revenue in Q2 Following License Deal with Astellas Institute	20/06	MT
Healios K.K. Enters into License Agreement with Astellas Institute for Regenerative Medicine	19/06	CI
Healios Enters Alliance, Bond Purchase Deal with Alfresa	06/06	MT
Healios Partners with AND Medical Group; Set to Receive Upfront Payment of 60 Million Yen	10/04	MT
Healios K.K. Enters into Joint Research Agreement with AND Medical Group	09/04	CI
Healios Concludes Purchase of Athersys Assets, Becoming Sole Owner of MultiStem IP	04/04	MT
Healios K.K. completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC .	03/04	CI
Japanese Shares Hit Fresh 52-Week Peak Ahead of Inflation Data	26/02	MT
Healios Proposes Reduction of Capital Stock, Reserves, Surplus Appropriation	26/02	MT
Jefferies Adjusts Healios K.K.’s Price Target at 140 Yen From 170 Yen, Keeps at Hold	20/02	MT
Healios K.K. announced that it has received ¥2.2600715 billion in funding	09/02	CI
Healios K.K. and ProcellCure Inc. Announce Start of ARDS Clinical Trial in Japan	02/02	CI
Healios K.K. announced that it expects to receive ¥2.2600715 billion in funding	25/01	CI
Healios and ProcellCure Initiate Clinical Trial for ARDS Treatment	18/01	MT
Japanese Shares Finish Lower After Key Economic Data	18/01	MT
Healios K.K. and Its Wholly Owned Subsidiary ProcellCure Inc. Announce Submission of ARDS Clinical Trial Notification in Japan	18/01	CI
Healios' Ischemic Stroke Trial Data Published in JAMA Neurology Journal	18/01	MT
Healios Secures LOI on Joint Research with AND	17/01	MT
Healios K.K. AND Medical Group Enter into A Letter of Intent for A Basic Agreement for Joint Research	16/01	CI
Healios Steps In as Primary Bidder and Lender for Athersys’s Asset Sale Amidst Bankruptcy	10/01	MT
Healios K.K. entered into an asset purchase agreement to acquire Substantially all assets of ABT Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC for $2.8 million.	05/01	CI
Healios, Nobelpharma in Talks for Stem Cell Therapy Alliance for ARDS	28/12	MT
Healios Invests in Arktus Therapeutics at Undisclosed Amount	26/12	MT
Healios K.K. (TSE : 4593) agreed to acquire an unknown minority stake in Arktus Therapeutics Co., Ltd.	22/12	CI
California Institute for Regenerative Medicine Awards $1 Million from the California Institute for Regenerative Medicine for Healios' Hypo-immune UDC	30/23/30	CI

Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Healios K.K.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

174 JPY

Average target price

280 JPY

Spread / Average Target

+60.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HEALIOS K.K.	+5.45%	103M
VERTEX PHARMACEUTICALS INCORPORATED	+16.44%	122B
REGENERON PHARMACEUTICALS, INC.	+18.94%	114B
ARGENX SE	+19.62%	25.71B
BIONTECH SE	-25.37%	19.02B
GENMAB A/S	-20.21%	15.83B
BEIGENE, LTD.	-20.20%	15.32B
WUXI APPTEC CO., LTD.	-47.37%	14.88B
SAREPTA THERAPEUTICS, INC.	+59.91%	14.82B
NEUROCRINE BIOSCIENCES, INC.	+4.35%	14.1B

Bio Therapeutic Drugs

Healios K.K.

Equities

4593

JP3835100003

Biotechnology & Medical Research

Healios K.K. Announces Retirement of Ken Ishikawa, Director

Latest news about Healios K.K.

Chart Healios K.K.

Company Profile

Income Statement Evolution

Ratings for Healios K.K.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs